Showing results (121-130 of 243) with videos related to

Sort By:
Pageof 25
The Lancet. Oncology|October 20, 2019
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trialGiovanni L Ceresoli, Joachim G Aerts, Rafal Dziadziuszko, et al.
European Journal of Cancer (Oxford, England : 1990)|November 20, 2022
Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscleSami Antoun, Emilie Lanoy, Samy Ammari, et al.
Frontiers in Oncology|February 7, 2024
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus reportMyriam Mirza, Aseem Shrivastava, Cecile Matthews, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
NPJ Precision Oncology|May 13, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinibMai Nagasaka, Francesco Facchinetti, Ludovic Bigot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancerJean-Charles Soria, Alex A Adjei, Rastilav Bahleda, et al.
The Lancet. Respiratory Medicine|April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 studyTimothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.
British Journal of Cancer|November 26, 2019
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancerWungki Park, Laura Mezquita, Naoyuki Okabe, et al.
Clinical Lung Cancer|April 8, 2023
A Patient-Centered Model of Fast-Track Lung Cancer DiagnosisPauline Pradere, Caroline Caramella, Fares Ben Salem, et al.
Journal for Immunotherapy of Cancer|September 7, 2023
Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancerPierre Decazes, Samy Ammari, Younes Belkouchi, et al.
Pageof 25